Compound acetylisovalery tylosin tartrate pellet and preparation method thereof

Abstract

The invention discloses a compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet is made by wrapping a drug-loading pellet core by adopting a coating material, wherein the drug-loading pellet core comprises the following components in percentage by weight: 1-30% of acetylisovalery tylosin tartrate, 1-30% of sulfadimidine, 5-20% of lactose, 5-25% of corncob powder, 10-60% of starch, 15-35% of microcrystalline cellulose and 0.5-12% of pelletizing binding agent; and weight of the coating material is not more than 8% of the total weight of the compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet has a better clinical treatment effect, application amount of acetylisovalery tylosin tartrate can be reduced, and production cost can be saved; and drug release can be delayed, drug action time can be prolonged, and long-acting effect can be achieved, so that administration frequency is reduced and labour intensity can be alleviated.

Description

[0001] technical field [0002] The invention relates to a compound tyvalectin tartrate pellet and a preparation method thereof, belonging to the technical field of veterinary drug preparations. [0003] Background technique [0004] Acetylisovalery Tylosin Tartrate (Acetylisovalery Tylosin Tartrate) is a brand-new macrolide antibiotic commercialized by Echo Animal Health Products Co., Ltd., UK. It is a derivative of tylosin A produced by chemical modification, and has strong antibacterial activity against mycoplasma, spirochete, most gram-positive bacteria and some gram-negative bacteria, especially against mycoplasma ; Mainly used to prevent mycoplasma infection in chickens, turkeys and other animals, pig dysentery, infectious pleuropneumonia, panting disease, proliferative enteritis (PPE), etc. It is a special antibiotic for livestock and poultry. [0005] At present, the common tivalamectins on the market are ordinary premixes and soluble powders. Due to the simple pre...

AI Technical Summary

Problems solved by technology

[0005] At present, the common tivalamectins on the market are ordinary premixes and soluble powders. Due to the simple preparation process, the bioavailability of the drug is low, and it is easily affected by gastric acid, and the drug itself is easy to cause serious damage to the gastrointestinal tract. Ordinary preparations have a strong smell and bitter taste and are easy to scatter, resulting in poor palatability and reduced feed intake, so that the curative effect of the drug is reduced, and the desired effect cannot be achieved; A variety of ingredients such as acidifiers, high trace elements, electrolytes, etc. undergo chemical reactions, reducing the efficacy of the drug, and the number of administrations of ordinary preparations increases the labor intensity; and the Chinese patent application number "201110009247.6" discloses a Tylvalerin injection for breeding pigs and preparation method thereof, each 100 ml of injection contains 20 grams of acetylisovaleryl tylosin tartrate, 20-35 grams of propylene glycol, and 10-15 grams of N,N-diformyl acetamide , 2 to 4 grams of benzyl alcohol, 0.1 to 1.0 grams of di-tert-butyl p-cresol and the balance of glycerol triacetate

However, this kind of tivalamectin injection for pigs still has the disadvantages that the labor intensity is high, and the injection will cause strong stress to pigs.